BioNTech (BNTX) presented strong Phase 2 data for pumitamig (BNT327), a bispecific antibody targeting PD-L1 and VEGF-A, showing 72.7% and 63.6% objective response rates in lung cancer with manageable safety profile and potential for accelerated FDA approval via PFS endpoint. Key risks include regulatory approval uncertainty, competitive landscape with established drugs like Keytruda, and clinical trial execution risk across their 25+ ongoing trials.